ArticleOphthalmology and therapy2025
Therapeutic Plasma Exchange for Severe Optic Neuritis in a Region with a High Prevalence of Neuromyelitis Optica.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe treatment of severe optic neuritis (ON) is an emergency, and the role of therapeutic plasma exchange (PLEX) is still debated. The objective of this study was to evaluate the efficacy of the initial combination of parenteral corticosteroid therapy with therapeutic PLEX for the treatment of severe ON. This was a retrospective cohort study conducted between January 1998 and January 2023.
methodsTherapeutic PLEX was initiated concomitantly with intravenous corticosteroid therapy. The etiological diagnosis of ON was specified as follows: neuromyelitis optica, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and multiple sclerosis. Sixty-five eyes (74.7%) underwent therapeutic PLEX, and 22 eyes (25.3%) received corticosteroid therapy alone.
resultsThe mean time to treatment was 7.9 ± 11 days. At 1 year, the mean visual acuity of plasmapheresis patients was 5/10, and that of non-plasmapheresis patients was 1.5/10 (p = 0.008). Five (8.1%) eyes in the PLEX group and 7 (31.8%) eyes in the group treated with corticosteroids alone remained completely blind (p = 0.005). The retinal nerve fiber layer and ganglion cell layer thickness were greater in the PLEX group than in the group treated with corticosteroids alone, 74 ± 23.1 μm versus 59.7 ± 19.3 μm and 24.7 ± 4.3 μm versus 23.3 ± 5.4 μm, respectively. MOGAD and multiple sclerosis patients had the best final visual acuity, 6/10 and 10/10, respectively (p = 0.01). No serious incidents were observed.
conclusionThis is the largest series of severe ON observed in an Afro-descendant population and treated concomitantly with therapeutic PLEX and systemic corticosteroid therapy at the acute phase. Our study confirms the efficacy of therapeutic PLEX in treating severe ON.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.